Disease modelling:a new facility in CLS by McMillan, Sarah J.






Link to publication in Discovery Research Portal
Citation for published version (APA):
McMillan, S. J. (2015). Disease modelling: a new facility in CLS. Poster session presented at University of
Dundee. College of Life Sciences 2015 Research Symposium, Crieff, United Kingdom.
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 18. Mar. 2016
Disease Modelling: A New Facility in CLS
Sarah J. McMillan
Biological Services/Cell Signalling & Immunology
Model Systems Currently Available
Role of Facility
• To establish new models of disease or use currently available models to
meet scientific aims.
• To supply protocols and advice for planning regulated procedures
regarding animal model, techniques, concentrations and time points.
• To consult project licences and/or assist in writing and/or amending project
licences and study plans to enable experimentation.
• To teach techniques and encourage confidence in animal handling if
required.
Why Has CLS Established The Facility?
Aim: To maximise scientific output and to minimise adverse
welfare to the animals during regulated procedures.
• Facility will provide skilled assistance in the design, execution, analysis
and reporting of experimental studies involving regulated procedures.
• This will reduce the number of personal licence holders to ensure only
experienced, skilled workers are performing regulated procedures to
maintain the welfare of the animals.
• Having a disease modelling facility in-house rather than outsourcing
enables flexibility.
How To Approach The Facility
• E-mail a brief proposal or arrange an informal meeting to discuss the overall
scientific aim(s).
• Enquires to: s.j.mcmillan@dundee.ac.uk or internal telephone 85778.
• Followed by:
Consultation of project licence (PPL) and/or advice on writing a PPL and/or
amendment.
Assistance with associated paperwork e.g. animal orders, writing study
plans, use of resource unit computer software.
Calculation of full costings for each experiment.
Agreement on contribution of service on experimental days.
• Cost: There is no charge for the service at present however, all animal and
consumable costs will apply. The position is funded by the Wellcome Trust
until Sept 2016. If applying for new funding please enquire about costings for
this service from 2016.
• Location: Cell Signalling & Immunology, PRC lab, WTB2 South.
Cystic Fibrosis 
• Pseudomonas aeruginosa is a gram negative bacterium found in abundance in
the lungs of cystic fibrosis patients.
• Model of lung infection with associated neutrophil infiltration (Robert Ryan,
MMB).
• Experimental readouts:
 Effects on cell recruitment & mediators in response to Pseudomonas
aeruginosa.
 Comparison of bacterial counts in infected organs to test virulence factors
using GM bacteria and in cystic fibrosis-KO mice.
 Assess the rate of clearance of different bacterial strains.
Figure 2 shows the cellular differences in cytospins prepared from bronchoalveolar lavage (BAL)
from control PBS mice and mice treated with intranasal Pseudomonas aeruginosa (strain PA14) at
48h. The last panel shows an example of an infected mouse lung with peribronchiolar (Br =
bronchiole) and alveolar bed infiltration of inflammatory cells 48h post infection.
Models of infection in the pipeline
• Lung infection model of influenza (H1N1). E.g. to study the role of
macrophage receptors on recognition of the virus (Paul Crocker, CSI).
• Serratia marcescens, a gram negative bacterium is a common cause of
hospital-acquired infections. Establish a model of infection to study virulence
factors using GM bacteria (Sarah Coulthurst, MMB).
Characterisation of Immune & Inflammatory Responses
• Are there differences in B and T cell responses in your genetically modified
mice? Test using immunisation studies and measurement of serum
immunoglobulins.
• Are there effects on cell recruitment? Innate and adaptive immune responses
to stimuli.
• Generation of bone marrow chimeric mice.
 Technically demanding requiring accurate injection of cells.
 Skilled technical expertise available to ensure minimal adverse welfare to
the animal.
Listeriosis
• Listeria monocytogenes, a gram positive bacterium that is a common cause of
food poisoning.
• Establishing a model of infection with Mahima Swamy, CSI to study the
pathogenesis of gut epithelium infection and with Nicola Stanley-Wall, MMB to
study the impact virulence factors on the course of infection.
A.                                                     B.
Figure 3. (A) Schematic of the course of listeria infection after eating contaminated food. (B)
Example of model system where C57Bl6/J mice can be bioimaged (IVIS) following administration
of 5x109 CFU Listeria monocytogenes-EGDe-InA-mur-lux. Data shows significant bacterial load
in the intestines at 1h post infection (Bergmann et al, BMC Microbiology 2013, 13:90).
PBS               S.aureus
Staphylococcus aureus-induced pneumonia
• S. aureus is a gram positive bacterium commonly found in the airways of
patients with lung disease.
• Model of lung infection characterised by neutrophilic inflammation and
dissemination of bacteria to spleen and liver (James Chalmers, MMB).
• Experimental readouts:
 Effects on cell recruitment and cytokine responses in response to
S.aureus.
 Comparison of bacterial counts in infected organs to test virulence factors
using GM bacteria.
 Whole cell immunisation studies as a potential therapeutic.
Lung Liver
Figure 1. (A) Comparison of mouse lungs 24h following infection with S.aureus or PBS control.  
(B) CFU counts in the mouse lung and liver following infection with S.aureus.  
